Chemotherapy is often seen solely as a tumor-targeting treatment, yet new evidence reveals a paradox: the tissue injury it causes can reprogram the body’s defenses, influencing the risk of metastasis. Researchers from the University of Lausanne and collaborators reported that chemotherapy reshapes the gut-immune axis by inducing microbiota-derived indole-3-propionic acid (IPA), which reprograms myelopoiesis to curb monocyte-driven immunosuppression and metastasis in colorectal cancer (CRC). Read More

Bronchopulmonary dysplasia (BPD) is a chronic disease of the lungs that mainly affects premature newborns, especially those who receive mechanical ventilation, which can contribute to altering normal lung development. There are few treatment options with limited efficacy to improve the prognosis of BPD. Read More

Sensorion SA has announced a €60 million (US$72 million) financing, with a €20 million (US$24 million) strategic investment from Sanofi SA, as it advances its pipeline of therapies to restore, treat and prevent hearing loss disorders. Read More

Tetrapharm (Tetra Pharm Technologies ApS) has announced promising preclinical data for TPC-026 for the chronic treatment and long-term management of metabolic disorders, including obesity. The preclinical findings support TPC-026 as a differentiated therapeutic candidate, designed to address underlying disease mechanisms, rather than symptoms alone. Read More

Janssen Pharmaceutica NV has identified compounds targeting TAR DNA-binding protein 43 (TARDBP; TDP-43) acting as positron emission tomography (PET) imaging agents. They are designed for use in the diagnosis of neurological disorders. Read More

Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) can cause severe and lethal bronchiolitis and pneumonia among particularly vulnerable populations, mostly infants, the elderly and immunocompromised patients. Researchers from Vanderbilt University Medical Center have isolated and characterized novel antibodies that cross-neutralize RSV and hMPV. Read More

Despite the successful application of adoptive T-cell transfer with chimeric antigen receptor (CAR)-engineered T cells for the treatment of various hematologic malignancies, several other hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), still lack effective treatment options. Read More

Sunshine Lake Pharma Co. Ltd. has divulged heterocyclic fused ring compounds acting as pyruvate kinase PKLR activators potentially useful for the treatment of anemia, abetalipoproteinemia, hemolysis, hereditary spherocytosis, sickle cell disease and thalassemia. Read More

Evopoint Biosciences Co. Ltd. has patented 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors. They are described as potentially useful for the treatment of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, diabetes and arteriosclerosis. Read More

The serine/threonine kinase glycogen synthase kinase-3β (GSK-3β) plays a multifunctional role through its involvement in multiple signaling pathways. Because of its relevant role in Alzheimer’s disease (AD) pathogenesis, regulating GSK-3β activity has been proposed as a potential approach to target AD-related pathology. Read More

Boomray Co. Ltd. has disclosed new conjugates comprising a fibroblast activation protein-α (FAPα) inhibitor covalently linked to radiolabeled chelating agents through a linker. They are reported to be useful for the diagnosis and treatment of cancer, inflammation, atherosclerosis, fibrosis, metabolic and neurological disorders. Read More

Di’ao Group Chengdu Pharmaceutical Co. Ltd. has synthesized glucagon-like peptide-1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of hypertension, diabetes type 1, cerebral infarction, metabolic dysfunction-associated steatohepatitis (MASH; NASH), metabolic syndrome, obesity, arteriosclerosis and Parkinson’s disease, among others. Read More

Voltage-gated sodium channels, particularly Nav1.7, are highly expressed in peripheral sensory neurons and are crucial for pain signal conduction and signal transmission in the spinal dorsal horn. Because of their role in triggering pain, these channels are considered critical targets for analgesics. Systemic inhibition of Nav1.7 has been shown to abolish pain perception. Read More